These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34894345)

  • 1. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19.
    Leung E; Crass RL; Jorgensen SCJ; Raybardhan S; Langford BJ; Moore WJ; Rhodes NJ
    Clin Pharmacokinet; 2022 Feb; 61(2):155-165. PubMed ID: 34894345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
    Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J
    Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review.
    Jorgensen SCJ; Lapinsky SE
    Clin Microbiol Infect; 2022 Jan; 28(1):51-57. PubMed ID: 34438068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
    Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
    Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab: From Rheumatic Diseases to COVID-19.
    Raiteri A; Piscaglia F; Granito A; Tovoli F
    Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Swets MC; Moss RJ; Kor F; Hilarius D; Moes DJAR; Berkhout WE; van den Toorn LM; van den Oever NCG; de Valk R; Rosendaal FR; Hunfeld N; Groeneveld GH; de Boer MGJ
    Int J Infect Dis; 2023 Apr; 129():57-62. PubMed ID: 36738957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.
    Hong JY; Ko JH; Yang J; Ha S; Nham E; Huh K; Cho SY; Kang CI; Chung DR; Baek JY; Sohn YM; Park HJ; Lee B; Huh HJ; Kang ES; Suh GY; Chung CR; Peck KR
    Yonsei Med J; 2022 May; 63(5):430-439. PubMed ID: 35512745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).
    Ullah S; Abid R; Haider S; Khuda F; Albadrani GM; Abdulhakim JA; Altyar AE; Abdel-Daim MM; Halimi SMA; Khalil AAK
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.
    Eşkazan AE; Balkan İİ; Demirbaş KC; Ar MC; Karaali R; Sekibağ Y; Mulamahmutoğlu S; Yartaş Dumanlı G; Çakmak F; Özgür Yurttaş N; Kurt F; Aladağ Kurt S; Kuşkucu M; Ürkmez S; Börekçi Ş; Saribal D; Mete B; Bavunoğlu I; Dikmen Y; Aygün G; Midilli K; Tabak F
    J Infect Chemother; 2021 Sep; 27(9):1329-1335. PubMed ID: 34120824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
    Malekzadeh R; Abedini A; Mohsenpour B; Sharifipour E; Ghasemian R; Javad-Mousavi SA; Khodashahi R; Darban M; Kalantari S; Abdollahi N; Salehi MR; Rezaei Hosseinabadi A; Khorvash F; Valizadeh M; Dastan F; Yousefian S; Hosseini H; Anjidani N; Tabarsi P
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107102. PubMed ID: 33075713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
    Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
    J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tocilizumab in COVID-19: A review of the current evidence.
    Alam W; Bizri AR
    Sci Prog; 2021; 104(3):368504211030372. PubMed ID: 34236264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.